INDIA – Takeda Biopharmaceuticals India Private Limited has launched its latest public health initiatives aimed at strengthening the health system for rare diseases (RD) in India.
This development comes as Takeda, a global pharmaceutical company based in Japan, is diligently expanding its pipeline to include yet another potential treatment for celiac disease.
Takeda is also in advanced talks with India’s medicine regulator, the Drug Controller General of India (DCGI), to roll out its dengue vaccine in the country.
The company focuses its Research & Development efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases.
In the same steps, Takeda affiliate in India is dedicated to discovering and delivering life-transforming treatments, guided by its commitment to patients, people and the planet.
Formerly Baxalta Bioscience India Private Limited, the company’s new public health initiatives will help to improve access to essential healthcare services for rare disease patients in India.
It will build on the Government of India’s efforts to bolster its health system provisions defined under the National Policy for Rare Diseases (NPRD 2021).
Ultimately, the new public initiatives of Takeda will pave the way for proper implementation of the NPRD 2021 and the development of sustainable funding options for the treatment of RD patients in India.
These public initiatives will focus on three key areas including spreading awareness amongst multiple stakeholders across the health sector and beyond about the rare disease cause and the policy provisions to support RD patients.
Moreover, the R&D-driven biopharmaceutical leader is exploring a roadmap and solutions for a sustainable funding mechanism for rare disease patients as per the Government of India guidelines and procedures.
Takeda also intends to experiment with the Hub and Spoke capacity building and mentoring model to ensure early diagnosis and management.
Through these initiatives, Takeda hopes to reduce the risk of patients developing childhood disabilities and life-long morbidity and early mortality, which progressively leads to poor quality of life.
This project reiterates Takeda’s commitment to addressing the unmet medical needs of patients living with rare diseases.
It is backed by Takeda’s partners, namely, APCO Worldwide, MAMTA Health Institute for Mother and Child, US-India Strategic Partnership Forum, and DakshamA Health and Education
As a global public affairs advisory and strategic communication firm working at the intersection of government, industry, and civil society, APCO Worldwide will facilitate better coordination between the treating hospitals and the donor ecosystem in India.
APCO Worldwide has already created the much-needed impetus in the healthcare ecosystem to collaborate better to identify pathways to financially support patients of rare disorders in the country.
At the same time, the new public initiatives of Takeda will build on the successes of The MAMTA and Takeda Public Health Initiative in straightening the health system in India.
MAMTA Health Institute has its own Technical Support Unit (TSU) framework to engage relevant partners in India associated with various national programs to improve the country’s health system.
The MAMTA and Takeda Public Health Initiative aims to replicate the best practices of the TSU in rare diseases to bring all the stakeholders together to improve access to healthcare in India.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
